[go: up one dir, main page]

RU2007125648A - Инденильные производные и их применение для лечения неврологических расстройств - Google Patents

Инденильные производные и их применение для лечения неврологических расстройств Download PDF

Info

Publication number
RU2007125648A
RU2007125648A RU2007125648/04A RU2007125648A RU2007125648A RU 2007125648 A RU2007125648 A RU 2007125648A RU 2007125648/04 A RU2007125648/04 A RU 2007125648/04A RU 2007125648 A RU2007125648 A RU 2007125648A RU 2007125648 A RU2007125648 A RU 2007125648A
Authority
RU
Russia
Prior art keywords
inden
dihydro
oxy
pyrrolidinyl
alkyl
Prior art date
Application number
RU2007125648/04A
Other languages
English (en)
Inventor
Дэвид Мэттью УИЛСОН (GB)
Дэвид Мэттью Уилсон
Original Assignee
Глэксо Груп Лимитед (GB)
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0426828A external-priority patent/GB0426828D0/en
Priority claimed from GB0519089A external-priority patent/GB0519089D0/en
Application filed by Глэксо Груп Лимитед (GB), Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед (GB)
Publication of RU2007125648A publication Critical patent/RU2007125648A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)

Claims (15)

1. Соединение формулы (I) или его фармацевтические приемлемая соль:
Figure 00000001
где
R1 представляет собой -X-C3-8 циклоалкил, -X-арил, -X-гетероциклил, -X-гетероарил, -X-С3-8 циклоалкил-Y-C3-8 циклоалкил, -X-С3-8 циклоалкил-Y-арил, -X-С3-8 циклоалкил-Y-гетероарил, -X-С3-8 циклоалкил-Y-гетероциклил, -X-арил-Y-C3-8 циклоалкил, -X-арил-Y-арил, -X-арил-Y-гетероарил, -X-арил-Y-гетероциклил, -X-гетероарил-Y-С3-8 циклоалкил, -X-гетероарил-Y-арил, -X-гетероарил-Y-гетероарил, -X-гетероарил-Y-гетероциклил, -X-гетероциклил-Y-С3-8циклоалкил, -X-гетероциклил-Y-арил, -X-гетероциклил-Y-гетероарил, -X-гетероциклил-Y-гетероциклил;
X представляет собой связь или С1-6 алкил;
Y представляет собой связь, С1-6 алкил, CO, CONH, COC2-6 алкенил, O, SO2 или NHCOC1-6 алкил;
R2 представляет собой галоген, С1-6 алкил, С1-6 алкокси, циано, амино;
m представляет собой целое число от 0 до 2;
n представляет собой целое число от 1 до 4;
R3 представляет собой водород, фтор или -С1-3 алкил;
p представляет собой целое число от 0 до 2;
где указанные алкильная, циклоалкильная, арильная, гетероарильная и гетероциклилическая группы R1 могут быть необязательно замещены одним или более заместителями (например, 1, 2 или 3), которые могут быть одинаковыми или различными и которые выбраны из группы, состоящей из галогена, гидрокси, циано, нитро, =O, галогенС1-6 алкила, галогенС1-6 алкокси, С1-6 алкила, С1-6 алкокси, арилС1-6 алкокси, С1-6 алкилтио, С1-6 алкоксиС1-6 алкила, С3-7 циклоалкилС1-6 алкокси, С1-6 алканоила, С1-6 алкоксикарбонила, С1-6 алкилсульфонила, С1-6 алкилсульфинила, С1-6 алкилсульфонилокси, С1-6 алкилсульфонилС1-6 алкила, сульфонила, арилсульфонила, арилсульфонилокси, арилсульфонилС1-6 алкила, арилокси, С1-6 алкилсульфонамидо, С1-6 алкиламино, С1-6 алкиламидо, -R4, -CO2R4, -COR4, С1-6 алкилсульфонамидоС1-6 алкила, С1-6 алкиламидоС1-6 алкила, арилсульфонамидо, арилкарбоксамидо, арилсульфонамидоС1-6 алкила, арилкарбоксамидоС1-6 алкила, ароила, ароилС1-6 алкила, арилС1-6 алканоила или группы -NR5R6, -С1-6 алкил-NR5R6, -С3-8 циклоалкил-NR5R6, -CONR5R6, -NR5COR6, -NR5SO2R6, -OCONR5R6, -NR5CO2R6, -NR4CONR5R6 или -SO2NR5R6 (где R4, R5 и R6 независимо представляют собой водород, С1-6 алкил, -С3-8 циклоалкил, -С1-6 алкил-С3-8 циклоалкил, арил, гетероциклил или гетероарил, или -NR5R6 может представлять собой азотсодержащую гетероциклическую группу, где упомянутые R4, R5 и R6 группы могут быть необязательно замещены одним или более заместителями (например, 1, 2 или 3), которые могут быть одинаковыми или различными и которые выбраны из группы, состоящей из галогена, гидрокси, С1-6 алкила, С1-6 алкокси, циано, амино, =O или галогенС1-6 алкила), при условии, что, если R1 представляет собой -С3-6 алкил, R1 не замещен гидрокси, С1-6 алкоксикарбонилом или -CO2R4;
или их сольваты.
2. Соединение по п.1, в котором R1 представляет собой -X-арил, -X-арил-Y-гетероциклил, -X-гетероциклил-Y-гетероциклил, -X-гетероарил или -X-гетероарил-Y-гетероциклил.
3. Соединение по п.2, в котором R1 представляет собой:
-X-гетероарил, необязательно замещенный -CONR6R7-группой, -CO2R4-группой или атомом галогена; или
-X-гетероарил-Y-гетероциклил, необязательно замещенный по гетероциклической группе оксогруппой и/или -R4-группой.
4. Соединение по п.1, в котором X представляет собой связь.
5. Соединение по п.1, в котором Y представляет собой связь или CO.
6. Соединение по п.1, в котором m представляет собой 0.
7. Соединение по п.1, в котором n представляет собой 2.
8. Соединение по п.1, в котором p представляет собой 0.
9. Соединение по п.1, которое представляет собой:
N-метил-6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинкарбоксамид;
5-бром-2-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}пиридин;
1-(6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинил)-2-пирролидинон, включая его (+) и (-) энантиомеры;
метил-5-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-2-пиразинкарбоксилат;
5-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-2-пиразинкарбоновую кислоту;
6-{[2-(гексагидро-1H-азепин-1-ил)-2,3-дигидро-1H-инден-5-ил]окси}-N-метил-3-пиридинкарбоксамид;
6-({2-[(2R,5R)-2,5-диметил-1-пирролидинил]-2,3-дигидро-1H-инден-5-ил}окси)-N-метил-3-пиридинкарбоксамид;
6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинкарбоксамид;
N-(1-метилэтил)-6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинкарбоксамид;
5-(1-пирролидинилкарбонил)-2-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}пиридин;
N-этил-6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинкарбоксамид;
N,N-диметил-6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинкарбоксамид;
N-метил-5-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-2-пиразинкарбоксамид;
5-бром-2-({2-[(2S)-2-метил-1-пирролидинил]-2,3-дигидро-1H-инден-5-ил}окси)пиридин;
N-метил-6-{[2-(1-пиперидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинкарбоксамид;
N-метил-6-({2-[(2R)-2-метил-1-пирролидинил]-2,3-дигидро-1H-инден-5-ил}окси]-3-пиридинкарбоксамид;
N-метил-6-({2-[(2S)-2-метил-1-пирролидинил]-2,3-дигидро-1H-инден-5-ил}окси]-3-пиридинкарбоксамид;
1-[6-({2-[(2S)-2-метил-1-пирролидинил]-2,3-дигидро-1H-инден-5-ил}окси)-3-пиридинил]-2-пирролидинон;
(+)-энантиомер N-метил-6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинкарбоксамида;
(-)-энантиомер N-метил-6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинкарбоксамида;
5-иод-2-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}пиридин;
1-{5-[(4-бромфенил)окси]-2,3-дигидро-1H-инден-2-ил}пирролидин;
1-(4-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}фенил)-2-пирролидинон;
1-метил-3-(6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинил)-2-имидазолидинон;
3-(6-{[2-(1-пирролидинил)-2,3-дигидро-1H-инден-5-ил]окси}-3-пиридинил)-1,3-оксазолидин-2-он;
или его фармацевтически приемлемые соль или сольват.
10. Фармацевтическая композиция, включающая соединение формулы (I) по любому из пп.1-9, или его фармацевтически приемлемые соль или сольват и фармацевтически приемлемый носитель или инертный наполнитель.
11. Соединение по любому из пп.1-9 или его фармацевтически приемлемые соль или сольват для применения в терапии.
12. Соединение по любому из пп.1-9 или его фармацевтически приемлемые соль или сольват для применения в лечении неврологических заболеваний.
13. Применение соединения по любому из пп.1-9 или его фармацевтически приемлемых соли или сольвата для изготовления лекарственного средства для лечения неврологических заболеваний.
14. Способ лечения неврологических заболеваний, включающий введение нуждающемуся в этом пациенту эффективного количества соединения формулы (I) по любому из пп.1-9 или его фармацевтически приемлемых соли или сольвата.
15. Фармацевтическая композиция для применения в лечении неврологических заболеваний, включающий соединение формулы (I) по любому из пп.1-9, или его фармацевтически приемлемые соль или сольват и фармацевтически приемлемый носитель.
RU2007125648/04A 2004-12-07 2005-12-05 Инденильные производные и их применение для лечения неврологических расстройств RU2007125648A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0426828A GB0426828D0 (en) 2004-12-07 2004-12-07 Novel compounds
GB0426828.0 2004-12-07
GB0519089.7 2005-09-19
GB0519089A GB0519089D0 (en) 2005-09-19 2005-09-19 Novel compounds

Publications (1)

Publication Number Publication Date
RU2007125648A true RU2007125648A (ru) 2009-01-20

Family

ID=36121490

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007125648/04A RU2007125648A (ru) 2004-12-07 2005-12-05 Инденильные производные и их применение для лечения неврологических расстройств

Country Status (13)

Country Link
US (1) US20090306052A1 (ru)
EP (1) EP1833796A1 (ru)
JP (1) JP2008523006A (ru)
KR (1) KR20070091007A (ru)
AU (1) AU2005313550A1 (ru)
BR (1) BRPI0518841A2 (ru)
CA (1) CA2589831A1 (ru)
IL (1) IL183656A0 (ru)
MA (1) MA29084B1 (ru)
MX (1) MX2007006754A (ru)
NO (1) NO20073113L (ru)
RU (1) RU2007125648A (ru)
WO (1) WO2006061193A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
NZ611323A (en) 2006-06-23 2014-10-31 Abbvie Bahamas Ltd Cyclopropyl amine derivatives as histamin h3 receptor modulators
WO2009063953A1 (ja) 2007-11-13 2009-05-22 Taisho Pharmaceutical Co., Ltd. フェニルピラゾール誘導体
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
CN103958499A (zh) 2011-12-08 2014-07-30 大正制药株式会社 苯基吡咯衍生物
US20150045553A1 (en) 2011-12-27 2015-02-12 Taisho Pharmaceutical Co., Ltd Phenyltriazole derivative
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545673A1 (de) * 1965-05-13 1969-08-28 Albert Ag Chem Werke Verfahren zur Herstellung von pharmazeutisch wirksamen Derivaten des 2-Aminoindans
US3943149A (en) * 1972-11-10 1976-03-09 E. R. Squibb & Sons, Inc. Naphthyloxy acetic acids and related compounds
JPH01503777A (ja) * 1985-10-04 1989-12-21 マツジヨ‐ニ‐ウインスロツプ・ソチエタ・ペル・アチオニ 縮合脂環式アミノアルコール類
ATE187436T1 (de) * 1993-08-06 1999-12-15 Upjohn Co 2-aminoindane als selektive dopamin-d3-liganden
DE602004009905T2 (de) * 2003-03-07 2008-08-28 Eli Lilly And Co., Indianapolis 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten

Also Published As

Publication number Publication date
US20090306052A1 (en) 2009-12-10
NO20073113L (no) 2007-07-16
BRPI0518841A2 (pt) 2008-12-09
EP1833796A1 (en) 2007-09-19
CA2589831A1 (en) 2006-06-15
KR20070091007A (ko) 2007-09-06
AU2005313550A1 (en) 2006-06-15
MX2007006754A (es) 2007-07-09
MA29084B1 (fr) 2007-12-03
WO2006061193A1 (en) 2006-06-15
JP2008523006A (ja) 2008-07-03
IL183656A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
RU2435757C2 (ru) Производные 3-циклил-2-(4-сульфамоилфенил)-n-циклилпропионамида, применимые для лечения нарушенной переносимости глюкозы и диабета
DK2496084T3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF colitis
RU2497813C2 (ru) 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
RU2007125648A (ru) Инденильные производные и их применение для лечения неврологических расстройств
RU2342383C2 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5
JP2006500348A5 (ru)
RU2008136187A (ru) Новое производное кумарина, обладающее противоопухолевой активностью
JP2006506373A5 (ru)
RU2012104493A (ru) Замещенные соединения пиразоло [1,5-a] пиримидина как ингибиторы киназы trk
JP2007508346A5 (ru)
RU2008112683A (ru) Ингибиторы fap
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
RU2003126233A (ru) Конденсированные циклические соединения и их использование в медицине
RU2006112593A (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk
RU2006137716A (ru) Ингибиторы гистондеацетилазы
RU2010116821A (ru) N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr
RU2005102004A (ru) Замещенные хинолины как антагонисты рецептора ccr5
RU2009133259A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
RU2005109561A (ru) Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции
RU2002131640A (ru) Ингибиторы дипептидилпептидазы iv
RU2010109898A (ru) Соединения индола и индазола в качестве ингибитора некроза клетки
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
RU2006138433A (ru) Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20090216

FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20090216